Lupin launches Prucalopride tablets in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Prucalopride Tablets, 1 mg, and 2 mg, in the United States, following the recent approval of its Abbreviated New Drug Application (ANDA) from the U.S. FDA.

Prucalopride Tablets are bioequivalent to Motegrity® Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc., and indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Prucalopride Tablets, 1 mg, and 2 mg (RLD Motegrity®) had estimated annual sales of USD 184 million in the U.S. (IQVIA MAT April 2025).

Shares of Lupin Limited was last trading in BSE at Rs. 1935.20 as compared to the previous close of Rs. 1930.70. The total number of shares traded during the day was 8208 in over 1014 trades.

The stock hit an intraday high of Rs. 1959.70 and intraday low of 1924.15. The net turnover during the day was Rs. 15897873.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA ANDA Approval PrucaloprideTablets